AI MARKET SCANNING

CG Oncology, Inc.

📅 Next Catalyst: Nov 09, 2026 (☀️ Open) 🏛️ NASDAQ 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP -0.40%
MAX GAP RECORD -3.78%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $CGON
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 09, 2026 Earnings Release 2026-11-09 (BEFORE OPEN (07:00)) 🔮 UPCOMING 🔒
Aug 07, 2026 Earnings Release 2026-08-07 (BEFORE OPEN)
+0.16%
May 07, 2026 Earnings Release 2026-05-07 (BEFORE OPEN)
+0.22%
Feb 27, 2026 Earnings Release 2026-02-27 (BEFORE OPEN)
-0.57%
Nov 14, 2025 Earnings Release 2025-11-14 (BEFORE OPEN)
+0.69%
Aug 08, 2025 Earnings Release 2025-08-08 (BEFORE OPEN)
+0.66%
May 13, 2025 Earnings Release 2025-05-13 (BEFORE OPEN)
-3.78%
Mar 28, 2025 Earnings Release 2025-03-28 (BEFORE OPEN)
-1.15%

VOLATILITY & GAP BIAS

AVG GAP MOVE 0.7%
Bullish Gaps (0)
Bearish Gaps (2)
Neutral / Flat (8)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $CGON

EXECUTIONS1 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
2026-10-30 🔒 PRO RADAR ••• x• $•••.•• → $•••.•• 57m +3.37%
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗